Scienture reports preliminary Q3 2026 revenue of $1.22 million, up sharply on Rezenopy launch
The company's second FDA-approved product, Rezenopy nasal spray, began commercial shipments in August 2026, lifting preliminary quarterly revenue alongside continued Arbli growth.
SEC filing